נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 5 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
פרוויג'יל
teva israel ltd - modafinil - קפליות - modafinil 100 mg - modafinil - modafinil - to improve wakefulness in patients with excessive sleepiness associated with narcolepsy (with or without cataplexy), obstructive sleep apnea/hypopnea syndrome ( osahs ) and shift work sleep disorder (swds).
טאלץ 80 מג
eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab
נובואייט 1000 יחבל
novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1000 iu / 4 ml - coagulation factor viii
נובואייט 1500 יחבל
novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii
נובואייט 2000 יחבל
novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 2000 iu / 4 ml - coagulation factor viii
נובואייט 250 יחבל
novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 250 iu / 4 ml - coagulation factor viii
נובואייט 3000 יחבל
novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 3000 iu / 4 ml - coagulation factor viii